- Home
- LIEN vs LXRX Comparison
LIEN vs LXRX Comparison
Compare LIEN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- LXRX
- Stock Information
- Founded
- LIEN 2021
- LXRX 1995
- Country
- LIEN United States
- LXRX United States
- Employees
- LIEN N/A
- LXRX N/A
- Industry
- LIEN
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- LXRX Health Care
- Exchange
- LIEN NYSE
- LXRX Nasdaq
- Market Cap
- LIEN 234.6M
- LXRX 228.8M
- IPO Year
- LIEN 2022
- LXRX 2000
- Fundamental
- Price
- LIEN $10.12
- LXRX $0.90
- Analyst Decision
- LIEN Buy
- LXRX Buy
- Analyst Count
- LIEN 2
- LXRX 4
- Target Price
- LIEN N/A
- LXRX $3.67
- AVG Volume (30 Days)
- LIEN 38.1K
- LXRX 4.0M
- Earning Date
- LIEN 08-07-2025
- LXRX 07-31-2025
- Dividend Yield
- LIEN 13.44%
- LXRX N/A
- EPS Growth
- LIEN 30.25
- LXRX N/A
- EPS
- LIEN 1.15
- LXRX N/A
- Revenue
- LIEN $30,828,508.00
- LXRX $31,213,000.00
- Revenue This Year
- LIEN $154.46
- LXRX N/A
- Revenue Next Year
- LIEN $10.64
- LXRX N/A
- P/E Ratio
- LIEN $8.77
- LXRX N/A
- Revenue Growth
- LIEN 151.96
- LXRX 1251.21
- 52 Week Low
- LIEN $9.70
- LXRX $0.28
- 52 Week High
- LIEN $13.38
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- LXRX 72.61
- Support Level
- LIEN N/A
- LXRX $0.64
- Resistance Level
- LIEN N/A
- LXRX $0.77
- Average True Range (ATR)
- LIEN 0.00
- LXRX 0.07
- MACD
- LIEN 0.00
- LXRX 0.01
- Stochastic Oscillator
- LIEN 0.00
- LXRX 93.90
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.